​

Climb Bio (CLYM) Stock Forecast, Price Target & Predictions

OverviewChart

CLYM Stock Forecast

Climb Bio (CLYM) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $21.88, with a high of $35.00 and a low of $17.00. This represents a 96.41% increase from the last price of $11.14.

CLYM Stock Rating

Climb Bio stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

CLYM Price Target Upside V Benchmarks

TypeNameUpside
StockClimb Bio96.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts289
Avg Price Target$27.50$21.88$20.67
Last Closing Price$11.14$11.14$11.14
Upside/Downside146.86%96.41%85.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26112---13
May, 26112---13
Apr, 26111---12
Mar, 2617---8
Feb, 26-7---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 08, 2026Guggenheim$35.00$10.55231.75%214.18%
May 12, 2026Raghuram SelvarajuH.C. Wainwright$20.00$11.1279.86%79.53%
May 08, 2026Wedbush$17.00$12.0640.96%52.60%
May 06, 2026Robert W. Baird$21.00$11.4583.41%88.51%
May 05, 2026Chardan Capital$22.00$9.69127.04%97.49%
Apr 15, 2026Joseph CatanzaroMizuho Securities$18.00$8.85103.39%61.58%
Mar 17, 2026Danielle BrillTruist Financial$17.00$7.12138.76%52.60%
Mar 10, 2026Christopher RaymondRaymond James$25.00$7.33241.06%124.42%
Dec 18, 2025Raghuram SelvarajuH.C. Wainwright$11.00$4.25158.82%-1.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 08, 2026GuggenheimBuyinitialise
May 12, 2026H.C. WainwrightBuyBuyhold
May 08, 2026WedbushOutperformOutperformhold
Mar 24, 2026B. RileyBuyinitialise
Mar 10, 2026Raymond JamesStrong Buyinitialise
Feb 13, 2026Piper SandlerOverweightinitialise
Dec 18, 2025H.C. WainwrightBuyBuyhold
Oct 13, 2025H.C. WainwrightBuyinitialise
Sep 30, 2025BTIGBuyBuyhold
May 22, 2025BTIGBuyinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast$-1.57$-0.62$-0.79$-1.10$-1.73$-2.69
High Forecast$-1.57$-0.62$-0.79$-1.10$-1.73$-2.69
Low Forecast$-1.57$-0.62$-0.79$-1.10$-1.73$-2.69
Surprise %------

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-73.90M-----
Avg Forecast$-101.64M$-40.14M$-51.14M$-71.21M$-112.00M$-174.15M
High Forecast$-101.64M$-40.14M$-51.14M$-71.21M$-112.00M$-174.15M
Low Forecast$-101.64M$-40.14M$-51.14M$-71.21M$-112.00M$-174.15M
Surprise %-27.29%-----

CLYM Forecast FAQ

Is Climb Bio stock a buy?

Climb Bio stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Climb Bio is a favorable investment for most analysts.

What is Climb Bio's price target?

Climb Bio's price target, set by 5 Wall Street analysts, averages $21.88 over the next 12 months. The price target range spans from $17 at the low end to $35 at the high end, suggesting a potential 96.41% change from the previous closing price of $11.14.

How does Climb Bio stock forecast compare to its benchmarks?

Climb Bio's stock forecast shows a 96.41% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Climb Bio over the past three months?

  • June 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Climb Bio’s EPS forecast?

Climb Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.62, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-0.79 in 2026, $-1.1 in 2027, $-1.73 in 2028, and $-2.69 in 2029.

What is Climb Bio’s revenue forecast?

Climb Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, $0 for 2028, and $0 for 2029.

What is Climb Bio’s net income forecast?

Climb Bio's net income forecast for the fiscal year ending in December 2025 stands at $-40.138M, representing a -45.68% decrease from the reported $-73.897M in 2024. Projections indicate $-51.143M in 2026, $-71.212M in 2027, $-112M in 2028, and $-174M in 2029.